ClinicalTrials.gg
RecruitingNCT07275515DARLENEUpdated May 28, 2026

DIROXIMEL FUMARATE TO REDUCE PERIHAEMATOMAL OEDEMA IN INTRACEREBRAL HAEMORRHAGE: DOUBLE BLIND RANDOMIZED CLINICAL TRIAL

A Phase 2 interventional study of DRF and Placebo in Stroke, sponsored by University Hospital, Lille. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-28.

Sponsored by University Hospital, Lille · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
192
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 15 studies in Stroke by University Hospital, Lille — 4 open to participants now, 4 under way, none of them phase 3. Stroke · University Hospital, Lille.

Started
2026
with 1 other
Phase 2
Only one
of the 15
Registered
14th of 15
by date

Among the 15 studies in Stroke by University Hospital, Lille, this one is one of 2 that started in 2026, is the only one in phase 2, and was the 14th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

4 of the 15 studies in Stroke by University Hospital, Lille are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Stroke by University Hospital, Lille, or all of them as a file.
02

Study summary

Spontaneous intracerebral haemorrhage (ICH) is a life-threatening condition, still devoided of specific treatment. Peri-haematomal oedema (PHO) develops in the ensuing days after ICH onset and worsens functional outcome. Hence, PHO is a promising therapeutic target but until now there is no specific treatment for PHO. The occurrence and growth of PHO is mainly mediated by inflammation. We hypothesize that a modulation of inflammation is effective in reducing PHO growth, therefore improving the functional outcome of ICH patients. From animal studies to human post-mortem studies, our team has demonstrated a key role for erythroid-related nuclear factor 2 (Nrf2) in PHO. Indeed, this transcription factor promotes the protective effect of inflammation: Nrf2 activation enhances antioxidant defenses and increases rates of blood resorption. Therefore, Nrf2 emerges as a promising and innovative therapeutic target. Taking into account the prolonged time interval between de novo drug discovery and use in clinical practice, drug repurposing is an interesting option for the unmet clinical need of reducing PHO. We chose Diroximel Fumarate (DRF) which is a safe and effective Nrf2 activator widely used in multiple sclerosis (dimethyl fumarate is on the market since 2013, and DRF since 2019) to modulate inflammation and to establish the efficacy of Nrf2 activation in reducing PHO growth and, ultimately, in improving the functional prognosis after ICH.

03

Conditions studied

  • Stroke

Browse trials for

Keywords

  • proof of concept
  • multicenter
  • stroke
  • randomization
  • double-blind, placebo-controlled
  • France
  • DRF group VS Placebo group
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients 18 years or older (no upper age limit)
  2. Patients admitted for a first-ever or recurrent (occurred more than 1 year before) symptomatic supratentorial spontaneous ICH confirmed by brain imaging
  3. Administration of study treatment no later than 48 hours after symptom onset or since last seen normal
  4. Written consent obtained
  5. Patient with social insurance in France
  6. Patient willing to comply with all study procedures and duration

Exclusion criteria

Exclusion Criteria:

  1. Massive ICH for medicinal product seems futile (hematoma volume is estimated > 60ml)
  2. Severe coma (Glasgow Coma Scale \<6)
  3. Pure intraventricular hemorrhage
  4. ICH suspected to result from a preceding trauma, an identified intracranial vascular malformation, venous thrombosis, tumor or hemorrhagic transformation within an infarct
  5. Patient planned for surgical evacuation of ICH before randomization (Evacuation, Decompressive hemicraniectomy, External ventricular drain)
  6. Patient with a known indication for DRF treatment (e.g. multiple sclerosis) or any other NrF2 agonist (dimethyl fumarate; Tecfidera)
  7. Patient with to DRF: patients with known to DRF, or to any of the of VUMERITY (patients taking dimethyl fumarate)
  8. Severe lymphopenia at admission (lymphocyte counts \< 0.5 x 109/L)
  9. Medical history: Suspected or confirmed of progressive multifocal leukoencephalopathy
  10. Severe swallowing disorder and/or nasogastric tube required
  11. Severe pre-ICH dependency (modified Rankin score of 5)
  12. \< 1 year related to comorbidities
  13. Late-stage organ (acute cardiac, renal or hepatic failure)
  14. Decision already taken for palliative (end of life) care with withdrawal of active treatment
  15. Pregnancy or breastfeeding or Women of childbearing age without effective (a pregnancy test will be done)
  16. Adults who are deprived of their liberty by judicial or administrative decision
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
192 participants (estimated)

Study arms

  • Experimental
    DRF group

    2\*231 mg of Diroximel Fumarate (DRF) per day for 7 days then 4\*231 mg per day for 14 days.

    Drug: DRF

  • Placebo comparator
    Placebo group

    2 capsules of matching placebo per day for 7 days than 4 capsules of matching placebo per day for 14 days.

    Drug: Placebo

Interventions

  • DrugDRF

    2\*231 mg of Diroximel Fumarate (DRF) per day for 7 days then 4\*231 mg per day for 14 days.

  • DrugPlacebo

    2 capsules of matching placebo per day for 7 days than 4 capsules of matching placebo per day for 14 days.

06

What researchers measure

Primary outcomes

  1. Absolute volume of PHO assessed at 8 ± 1 days with brain non-contrast CT (NCCT) scan.

    Time frame: at 8 ± 1 days

Secondary outcomes

  1. Functional outcome: global disability assessed by overall distribution of mRS score at 6 months (end of follow-up) (shift analysis)

    Time frame: at 6 months

  2. The rate of severe adverse events occurring between the date of randomization and the end of follow-up (six-month visit).

    Time frame: At 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for May 2029, 36 months after the start.

Of 112 non-industry phase 2 interventional studies under Stroke, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 60. This study's planned 36 months is below that.

Counting every sponsor, half of 132 studies reached it within 40 months; a quarter within 24 and three quarters within 59.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2025
First posted
Dec 10, 2025
StartActual
May 19, 2026
Primary completionEst.
May 2029
CompletionEst.
May 2029
Last update
May 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07275515
Collaborators
Ministère de la Santé
Responsible party
Sponsor
First posted
Dec 10, 2025
Start date
May 19, 2026
Primary completion
May 2029 (estimated)
Completion
May 2029 (estimated)
Last update
May 28, 2026

Study contacts

Laurent PUY
Contact
laurent.puy@univ-lille.fr
0320446814 ext. +33

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion